Share this video  

ASCO 2017 | Combining agents to improve response rates in genitourinary cancer

Andrea Apolo, MD from the National Cancer Institute at the Memorial Sloan-Kettering Cancer Center, Bethesda, MD discusses the agents that have been FDA approved for metastatic advanced bladder cancer, and the efforts to improve the activity of these agents. The recently FDA approved agents have a range of overall response rate between 15-20%, and this can be improved by combining the agents with other drugs, to enhance the immune system which allows the tumor to become more responsive to checkpoint inhibitors. There are many ongoing trials that are investigating the response rates of a combination of agents, one such trial investigates the combination of nivolumab and cabozantinib, with or without ipilimumab (NCT02496208) in treating patients with metastatic genitourinary tumors, and the results of this trial have been very encouraging, although not conclusive. It is crucial to identify the most optimal combination, therefore many more are still being tested and investigated. Recorded at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL